Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma

Next Previous
Trial Profile

Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Jan 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
    • 12 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 12 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top